Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) Receives Consensus Recommendation of “Buy” from Analysts
Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) has received an average recommendation of “Buy” from the twelve analysts that are covering the firm. Three equities research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $42.00.
Several equities research analysts recently commented on the stock. Stifel Nicolaus upped their price target on shares of Zeltiq Aesthetics from $38.00 to $52.00 and gave the company a “buy” rating in a research report on Wednesday, September 21st. Leerink Swann restated an “outperform” rating and issued a $48.00 price target on shares of Zeltiq Aesthetics in a research report on Thursday, August 25th. Zacks Investment Research upgraded shares of Zeltiq Aesthetics from a “sell” rating to a “hold” rating in a research report on Friday, August 12th. JPMorgan Chase & Co. restated a “hold” rating and issued a $35.00 price target (up previously from $27.00) on shares of Zeltiq Aesthetics in a research report on Tuesday, August 9th. Finally, Brean Capital set a $39.00 price target on shares of Zeltiq Aesthetics and gave the company a “buy” rating in a research report on Tuesday, August 9th.
In other news, insider Keith J. Sullivan sold 8,000 shares of the stock in a transaction on Monday, July 11th. The shares were sold at an average price of $30.02, for a total transaction of $240,160.00. Following the transaction, the insider now owns 77,922 shares in the company, valued at approximately $2,339,218.44. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Bradley Hauser sold 3,000 shares of the stock in a transaction on Monday, July 11th. The stock was sold at an average price of $30.02, for a total transaction of $90,060.00. Following the transaction, the vice president now owns 47,184 shares in the company, valued at approximately $1,416,463.68. The disclosure for this sale can be found here. Insiders own 15.60% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Texas Permanent School Fund acquired a new position in shares of Zeltiq Aesthetics during the first quarter valued at approximately $695,000. Nisa Investment Advisors L.L.C. acquired a new position in shares of Zeltiq Aesthetics during the first quarter valued at approximately $1,575,000. Prudential Financial Inc. acquired a new position in shares of Zeltiq Aesthetics during the first quarter valued at approximately $2,049,000. BlackRock Group LTD raised its position in Zeltiq Aesthetics by 278.1% in the first quarter. BlackRock Group LTD now owns 30,785 shares of the company’s stock worth $837,000 after buying an additional 22,642 shares during the last quarter. Finally, BlackRock Fund Advisors raised its position in Zeltiq Aesthetics by 134.5% in the first quarter. BlackRock Fund Advisors now owns 2,098,036 shares of the company’s stock worth $56,983,000 after buying an additional 1,203,254 shares during the last quarter.
Shares of Zeltiq Aesthetics (NASDAQ:ZLTQ) traded up 1.67% during mid-day trading on Thursday, reaching $40.84. 419,653 shares of the company were exchanged. The company has a market capitalization of $1.62 billion, a price-to-earnings ratio of 61.41 and a beta of 0.79. Zeltiq Aesthetics has a 12 month low of $18.41 and a 12 month high of $41.43. The firm’s 50-day moving average is $38.56 and its 200-day moving average is $31.71.
Zeltiq Aesthetics (NASDAQ:ZLTQ) last released its earnings results on Monday, August 8th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.07. Zeltiq Aesthetics had a net margin of 9.54% and a negative return on equity of 9.90%. The business had revenue of $89.50 million for the quarter, compared to analyst estimates of $79.68 million. During the same period in the prior year, the company earned $0.03 earnings per share. The firm’s revenue for the quarter was up 38.9% on a year-over-year basis. On average, equities analysts forecast that Zeltiq Aesthetics will post ($0.13) earnings per share for the current fiscal year.
About Zeltiq Aesthetics
ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.
Receive News & Ratings for Zeltiq Aesthetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.